

5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference – Cutting Edge Innovations in Cancer Therapy

PUNE, MH, INDIA, May 30, 2022

/EINPresswire.com/ --

The search for a cure for cancer can quite possibly be proclaimed as the holy grail of modern medicine. The journey has been a tremendous & tireless pursuit, selflessly undertaken by doctors, researchers, scientists & the entire healthcare community.

The turn of the century has seen an unprecedented advancement in technological innovations which have helped optimize the healthcare ecosystem & provided the infrastructure for novel techniques to flourish.

'Immunotherapy' or 'Immuno-oncology' happens to be one of the key discoveries in the global battle against cancer. Harnessing the power of AI & Big Data analysis, doctors & scientists are making inroads into developed various schemes of personalized medicine & targeted therapies suited for an individual's genetic makeup. Detecting the presence of biomarkers & via next-gen sequencing, medical workers are being able to plan the most efficient treatments to cope & adequately fight against tumors.

The 5TH ANNUAL MARKETSandMARKETS NEXT-GEN IMMUNO-ONCOLOGY CONFERENCE scheduled to be held in BOSTON, USA on the 23rd-24th of JUNE, 2022 will gather industry leaders with an aim to explore the future roadmap, challenges & more importantly allow for cross-discipline sharing of knowledge to promote eventual collaboration and progress.

KEY HIGHLIGHTS & NOTEWORTHY TOPICS OF DISCUSSION:

- Updates in development of monoclonal antibodies, ADC's and Bispecific Ab's
- Immune Checkpoint Inhibitors and Combination Therapies
- Preclinical & Translational Immuno-Oncology Developments
- Biomarkers and Cancer Vaccines
- CAR-T cell therapy, Adoptive-T Cell Therapy



- Tumor microenvironments
- Oncolytic Viruses
- Microbiome in IO & Neoantigens
- Personalized Cancer Immunotherapy

A GLIMPSE OF THE EXPERT SPEAKER PANEL:

- DYSTEIN REKDAL, CEO, LYTX BIOPHARMA
- JOHN ROSSI, SVP, Head, Translational Medicine, CERO THERAPEUTICS
- LOKESH AGRAWAL, Program Director, Biorepositories and Biospecimen Research Branch (BBRB), NCI, NIH
- ALISON CRAWFORD, Associate Director of Immuno-oncology, REGENERON PHARMACEUTICALS
- SAM SHRIVASTAVA, CEO, Founder, ASHA THERAPEUTICS
- PAUL LAMMERS, President & CEO, TRIUMVIRA IMMUNOLOGICS
- SHAHRAM SALEK ARDAKANI, Chief Scientific Officer, JANUX THERAPEUTICS
- TOBI LIMKE, CEO, PROMOCCELL
- JENNIFER ELLIOTT, Senior Director, Oncology & Precision Medicine, QIAGEN
- BARAJIT MUKHERJEE, Asst. Professor, Oncology, ROSWELL PARK COMPREHENSIVE CANCER CENTER
- RAJKUMAR NOUBADE, Senior Scientist, AMGEN

EVENT: 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference

WHEN: 23rd - 24th June 2022

WHERE: Boston, USA

[FIND OUT MORE. EXPLORE THE ENTIRE 2-DAY AGENDA HERE!](#)
[REGISTER FOR THE CONFERENCE!](#)

Ayush Kanitkar
 MarketsandMarkets
 +91 8975985061
events@marketsandmarkets.com

This press release can be viewed online at: <https://www.einpresswire.com/article/574261166>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.